FDA – Page 10 – Policy & Medicine

OPDP Sends Third Untitled Letter of the Year to Eton Pharmaceuticals

FDA Reconsidering the Need for Mandatory Opioid Prescriber Education

Woodcock Calls for HHS OIG Investigation Into Aduhelm Approval

FDA Finalizes Guidance on Field Alert Report Submissions

Amgen Receives Untitled Letter for Banner Ad Promoting Neulasta

FDA Releases Draft Guidance on Sponsor Safety Reporting Requirements

OPDP To Study Promotion of Prescription Drugs at HCP Conferences

FDA Approves New Alzheimer’s Drug

HHS and FDA Withdraw UDI Termination Notice

FDA Issues Notice of Noncompliance for Failure to Submit Clinical Trial Results Data